The United States Department of Defense has introduced a new policy requiring testosterone screening for active-duty military personnel aged 30 and older, with voluntary testing available for younger service members. Announced by Secretary of Defense Pete Hegseth, the initiative aims to assess and potentially address testosterone deficiency among troops, with replacement therapy offered to those with medically confirmed low levels.

Hegseth described the program as a step toward enhancing the physical resilience and overall readiness of service members, framing testosterone as a foundational element for sustaining combat effectiveness. The policy is expected to be incorporated into annual health evaluations, though details on the consequences for personnel who decline therapy remain unspecified. Notably, the announcement did not clarify how the policy will apply to female military members, who naturally have significantly lower testosterone levels compared to men.

The new testing protocol comes amid broader changes overseen by Hegseth since assuming his role, including renaming the Pentagon’s operations the Department of War, emphasizing a "warrior ethos," and making personnel decisions that critics say disproportionately affect women and minority officers. Reports indicate that Hegseth has blocked promotions for several senior officers, many of whom are women or people of color, sparking debate within military ranks about inclusivity and meritocracy.

Testosterone replacement therapy (TRT) itself remains a subject of medical debate. While concerns exist regarding potential risks such as cardiovascular issues, cancer growth, and increased aggression, recent studies offer conflicting evidence. Some research, including a 2015 study involving U.S. veterans, suggests TRT may reduce the risk of heart attacks and strokes. Expert panels have also challenged earlier assertions linking testosterone therapy to heightened prostate cancer risk.

Medical specialists note that testosterone deficiency is common among men over 40 and is associated with reduced muscle mass, bone density, energy levels, and sexual function. Advocates argue that correcting low testosterone to normal levels can improve physical and mental health, which may be especially relevant for individuals in demanding roles such as military service.

Historically, military policies have been cautious about service members using testosterone due to concerns over deployability and potential side effects. Advances in treatment, such as long-lasting injections, have made managing testosterone levels during deployments more feasible. Some military-backed research highlights the potential for TRT to mitigate the physical and psychological toll of sustained operational stress.

However, side effects of therapy, including infertility and hormonal imbalances, remain considerations. The broader context also recalls past instances where the military implemented widespread pharmaceutical measures with unintended long-term consequences, raising questions about the implications of this latest initiative.

As the Pentagon moves forward with its testosterone screening policy, questions remain about its implementation, particularly regarding female service members, informed consent, and the balance between enhancing performance and safeguarding health. The policy underscores ongoing efforts within the Department of Defense to redefine readiness and address the evolving demands placed on American troops.